(19)

(11)

EP 4 551 685 A1

(12)

(43) Date of publication: 14.05.2025 Bulletin 2025/20 (21) Application number: 23834338.8 (22) Date of filing: 05.07.2023

(51) International Patent Classification (IPC):  C12N 1/20(2006.01) A61K 35/741(2015.01) A61K 35/744(2015.01) A61P 1/12(2006.01) A23L 33/135(2016.01) A61K 35/742(2015.01) A61P 1/00(2006.01) C12Q 1/689(2018.01) (52) Cooperative Patent Classification (CPC): A23L 33/135; A61K 35/741; A61K 35/742; A61K 35/744; A61P 1/00; A61P 1/12; C12Q 1/689; C12R 2001/46; C12R 2001/225; C12N 1/205; A61K 35/747 (86) International application number: PCT/CA2023/050910 (87) International publication number: WO 2024/007079 (11.01.2024 Gazette 2024/02)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: KH MA MD TN (30) Priority: 05.07.2022 US 202263358336 P (71) Applicants: CANBIOCIN INC. Edmonton, Alberta T5J 4P6 (CA) The Adored Beast Apothecary Ltd. Toronto, Ontario M5A 1T7 (CA)	(72) Inventors: BURLET, John F. Edmonton, Alberta T5J 4P6 (CA) LEE, Julie Toronto, Ontario M5A 1T7 (CA) (74) Representative: Barker Brettell LLP  100 Hagley Road Edgbaston Birmingham B16 8QQ Birmingham B16 8QQ (GB)